Hepatitis C

I-MAK filed the first-ever U.S. patent challenges against sofosbuvir, the backbone of Sovaldi®, Harvoni®, and Epclusa®, arguing that the drug’s core patents do not meet the legal standards for novelty and non-obviousness. If Gilead’s eight patents are overturned, U.S. taxpayers will save more than $10 billion and generics will come to market 16 years earlier.

Partner with us now to build
a more just and equitable
medicine system for all.